The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.
Kathleen M. Fox, MHS, PhD
Advertisement
Articles by Kathleen M. Fox, MHS, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
2
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
3
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
4
Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk
5